Effects and mechanism ofandrographolide on diabetic nephropathy mice

LI Mengshi; WU Teng; CAO Jinghua; HE Yajun; QI Cuiling; WANG Lijing

doi:10.11665/j.issn.1000-5048.20180114

Journal of China Pharmaceutical University > 2018 > 49(1): 97-101. > DOI: 10.11665/j.issn.1000-5048.20180114

LI Mengshi, WU Teng, CAO Jinghua, HE Yajun, QI Cuiling, WANG Lijing. Effects and mechanism ofandrographolide on diabetic nephropathy mice[J]. Journal of China Pharmaceutical University, 2018, 49(1): 97-101. DOI: 10.11665/j.issn.1000-5048.20180114

Citation:

PDF (1962 KB)

Effects and mechanism ofandrographolide on diabetic nephropathy mice

More Information

Graphical Abstract

Abstract

Abstract

To investigate the effects and mechanism of andrographolide(Andro)on type II diabetic nephropathy in Lepr^db/dbmice, levels of urinary protein, serum creatinine and blood urea nitrogen after 24 h of Andro(1 mg/kg, ip)treatment on Lepr^db/db mice were measured by kit. The changes on renal pathology and sugar levels in diabetic mice treated by Andro were observed by HE staining and PAS staining. The expression of fibronectin(FN)and NOX-4 protein were analyzed by immunofluorescence. Results showed that levels of urinary protein, serum creatinine and blood urea nitrogenin Lepr^{db / db} mice after Andro treatment for 24 h were significantly lower than those of the control group. Kidney pathologic change was inhibited, and FN and NOX-4 expression were markedly decrease in the Andro group. In conclusion, Andro can significantly reduce the diabetic nephropathy in Lepr^db/db mice with spontaneous type II diabetes mellitus.
- andrographolide,
- diabetic nephropathy,
- Lepr^db/db mice,
- mesangial cells

FullText(HTML)

References (27)

References

[1]	Danaei G,Finucane MM,Lu Y,et al.National,regional,and global trends in fasting plasma glucose and diabetes prevalence since 1980:systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J].Lancet,2011,378(9785):31-40.
[2]	Sun H, Yuan Y, Sun ZL. Cholesterol contributes to diabetic nephropathy through SCAP-SREBP-2 Pathway[J].Int J Endocrinol,2013,2013:592576.
[3]	Forbes JM,Fukami K,Cooper ME.Diabetic nephropathy:where hemodynamics meets metabolism[J].Exp Clin Endocrinol Diabetes,2007,115(2):69-84.
[4]	Jerums G, Panagiotopoulos S, Premaratne E, et al. Integrating albuminuria and GFR in the assessment of diabetic nephropathy[J].Nat Rev Nephrol,2009,5(7):397-406.
[5]	Tramonti G,Kanwar YS.Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy[J].Endocrine,2013,43(3):494-503.
[6]	Zhang,XF,Tan BK.Anti-diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats[J].Acta Pharmacol Sin,2000,21(12):1157-1164.
[7]	Menini S,Amadio L,Oddi G,et al.Deletion of p66Shc longevity gene protects against experimental diabetic glomerulopathy by preventing diabetes-induced oxidative stress[J].Diabetes,2006,55(6):1642-1650.
[8]	Ji X, Li C, Ou Y, et al. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemiamediated renal oxidative stress and inflammation via Akt/NF-κB pathway[J].Mol Cell Endocrinol,2016,437:268-279.
[9]	Baynes JW.Role of oxidative stress in development of complications in diabetes[J].Diabetes,1991,40(4):405-412.
[10]	Giacco F,Brownlee M.Oxidative stress and diabetic complications[J].Circ Res,2010,107(9):1058-1070.
[11]	Schnackenberg CG.Oxygen radicals in cardiovascular-renal disease[J].Curr Opin Pharmacol,2002,2(2):121-125.
[12]	Gorin Y,Block K,Hernandez J,et al.Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney[J].J Biol Chem,2005,280(47):39616-39626.
[13]	Fujii M, Inoguchi T, Maeda Y, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice[J].Kidney Int,2007,72(4):473-480.
[14]	Sheeja K,Guruvayoorappan C,Kuttan G.Antiangiogenic activity of andrographis paniculata extract and andrographolide[J].Int Immunopharmacol,2007,7(2):211-221.
[15]	Sinha J, Mukhopadhyay S, Das N, et al. Targeting of liposomal andrographolide to L.donovani-infected macrophages in vivo[J].Drug Deliv,2000,7( 4):209-213.
[16]	Jada SR,Hamzah AS,Lajis NH,et al.Semisynthesis and cytotoxic activities of andrographolide analogues[J].J Enzyme Inhib Med Chem,2006,21(2):145-155.
[17]	Zhang Z,Jiang J,Yu P,et al.Hypoglycemic and beta cell protective effects of Andrographolide analogue for diabetes treatment[J].J Transl Med,2009,7:62.
[18]	Zhang C,Gui L,Xu Y,et al.Preventive effects of Andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance[J].Int Immunopharmacol,2013,16(4):451-456.
[19]	Yan GR,Zhou HH,Wang Y,et al.Protective effects of Andrographolide analogue AL-1 on ROS-induced RIN-mbeta cell death by inducing ROS generation[J].PLoS One,2013,8(6):e63656.
[20]	Dey SK,Bose D,Hazra A,et al.Cytotoxic activity and apoptosis-inducing potential of di-spiropyrrolidino and di-spiropyrrolizidino oxindole Andrographolide derivatives[J].PLoS One,2013,8(3):e58055.
[21]	Zhu YY, Yu G, Zhang Y, et al. A novel Andrographolide derivative AL-1 exerts its cytotoxicity on K562 cells through a ROS-dependent mechanism[J].Proteomics,2013,13(1):169-178.
[22]	Kaur M,Bedi O,Sachdeva S,et al.Rodent animal models:from mild to advanced stages of diabetic nephropathy[J].Inflammopharmacology,2014,22(5):279-293.
[23]	Fang WH.Drug treatment of diabetic nephropathy[J].Anhui Med Pharm J(安徽医药),2009,13(2):215-217.
[24]	Cheng SH,Hou FY,Zhang LJ.Investigation on curative effect of astragalus injection on ddiabetic nephrosis[J].Chin Tradit Pat Med(中成药),2000,22(3):207-209.
[25]	Lan T,Wu T,Gou H,et al.Andrographolide suppresses high glucose-induced fibronectin expression in mesangial cells via inhibiting the AP-1 pathway[J].J Cell Biochem,2013,114(11):2562-2568.
[26]	Hummel KP,Dickie MM,Coleman DL.Diabetes,a new mutation in the mouse[J].Science,1966,153(3740):1127-1128.
[27]	Brezniceanu ML,Liu F,Wei CC,et al.Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells[J].Diabetes, 2008,57(2):451-459.

[1]	LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
[2]	CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
[3]	FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
[4]	TANG Keqin, LIN Huaqing, LI Shuhong, DONG Lixin, LU Bohong, JIANG Hong. Advances in tumor targeted nanocrystals[J]. Journal of China Pharmaceutical University, 2020, 51(4): 418-424. DOI: 10.11665/j.issn.1000-5048.20200405
[5]	MEI Jiahao, HONG Ze, WANG Chen. Advances of drugs in targeting cGAS-STING signaling pathway[J]. Journal of China Pharmaceutical University, 2020, 51(3): 249-259. DOI: 10.11665/j.issn.1000-5048.20200301
[6]	JIANG Lu, CHEN Dandan, SUN Minjie, PING Qineng, ZHANG Can. Advances of wax matrix tablets[J]. Journal of China Pharmaceutical University, 2016, 47(4): 497-502. DOI: 10.11665/j.issn.1000-5048.20160418
[7]	YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
[8]	ZHANG Fangrong, WANG Wei. Advances of synthetic lipoproteins as drug nanovectors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 148-157. DOI: 10.11665/j.issn.1000-5048.20160204
[9]	LIU Fang, SUN Haopeng, YOU Qidong. Advances in small-molecule inhibitors targeting Hsp90-Cdc37 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2015, 46(3): 272-278. DOI: 10.11665/j.issn.1000-5048.20150303
[10]	WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303

Cited By

Get Citation

PDF

XML

Article views (805) PDF downloads (1536)

Turn off MathJax

Article Contents

Abstract

References

Effects and mechanism ofandrographolide on diabetic nephropathy mice

Abstract

References

Related Articles

Catalog

Effects and mechanism ofandrographolide on diabetic nephropathy mice

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content